WO2005020988A1 - Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity - Google Patents
Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity Download PDFInfo
- Publication number
- WO2005020988A1 WO2005020988A1 PCT/EP2004/051961 EP2004051961W WO2005020988A1 WO 2005020988 A1 WO2005020988 A1 WO 2005020988A1 EP 2004051961 W EP2004051961 W EP 2004051961W WO 2005020988 A1 WO2005020988 A1 WO 2005020988A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- prophylaxis
- juvenile
- phenyl
- chlorophenyl
- Prior art date
Links
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical class C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 title abstract description 7
- 230000000694 effects Effects 0.000 title description 4
- 238000011282 treatment Methods 0.000 claims abstract description 42
- 208000008589 Obesity Diseases 0.000 claims abstract description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 235000020824 obesity Nutrition 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 29
- 238000011321 prophylaxis Methods 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 25
- 230000000366 juvenile effect Effects 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 125000001424 substituent group Chemical group 0.000 claims abstract description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 229930003827 cannabinoid Natural products 0.000 claims description 12
- 239000003557 cannabinoid Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000020016 psychiatric disease Diseases 0.000 claims description 7
- -1 trifluoromethoxy, nitro, amino Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 150000002431 hydrogen Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000027559 Appetite disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 230000003042 antagnostic effect Effects 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 230000005062 synaptic transmission Effects 0.000 claims description 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 abstract description 10
- 230000003389 potentiating effect Effects 0.000 abstract description 4
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 2
- 240000004308 marijuana Species 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 208000021017 Weight Gain Diseases 0.000 description 10
- 235000019786 weight gain Nutrition 0.000 description 10
- 208000007683 Pediatric Obesity Diseases 0.000 description 9
- 230000004584 weight gain Effects 0.000 description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 239000003693 atypical antipsychotic agent Substances 0.000 description 6
- 229940127236 atypical antipsychotics Drugs 0.000 description 6
- 229940044551 receptor antagonist Drugs 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 6
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 3
- 108050007331 Cannabinoid receptor Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 241000218236 Cannabis Species 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 0 ***N1N=C(*)C(*)(*)C1 Chemical compound ***N1N=C(*)C(*)(*)C1 0.000 description 1
- QDNFIYLWAMNCGV-UHFFFAOYSA-N 1-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]-3-(4-chlorophenyl)sulfonylbutan-1-one Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)C(C)CC(=O)N(N=1)CC(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 QDNFIYLWAMNCGV-UHFFFAOYSA-N 0.000 description 1
- HRWGXPSWTHOGEW-UHFFFAOYSA-N 1-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]-3-(4-chlorophenyl)sulfonylpropan-1-one Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(=O)CCS(=O)(=O)C=2C=CC(Cl)=CC=2)CC1C1=CC=CC=C1 HRWGXPSWTHOGEW-UHFFFAOYSA-N 0.000 description 1
- YBMMBGKWEDRYNB-UHFFFAOYSA-N 2-(2-benzylsulfonylethyl)-5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazole Chemical compound C1=CC(Cl)=CC=C1C(C(C1)C=2C=CC=CC=2)=NN1CCS(=O)(=O)CC1=CC=CC=C1 YBMMBGKWEDRYNB-UHFFFAOYSA-N 0.000 description 1
- PTKMGIYABHEVJU-UHFFFAOYSA-N 3-(4-chlorophenyl)-4-phenyl-1,5-dihydropyrazol-4-ol Chemical compound C=1C=CC=CC=1C1(O)CNN=C1C1=CC=C(Cl)C=C1 PTKMGIYABHEVJU-UHFFFAOYSA-N 0.000 description 1
- SMGRKVJWSIFNAV-UHFFFAOYSA-N 3-(benzenesulfonyl)-1-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]propan-1-one Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(=O)CCS(=O)(=O)C=2C=CC=CC=2)CC1C1=CC=CC=C1 SMGRKVJWSIFNAV-UHFFFAOYSA-N 0.000 description 1
- NRGOZJYSRXOCFH-UHFFFAOYSA-N 4,5-bis(4-methoxyphenyl)-n'-(4-methoxyphenyl)sulfonyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(OC)=CC=C1C1C(C=2C=CC(OC)=CC=2)=NN(C(=N)NS(=O)(=O)C=2C=CC(OC)=CC=2)C1 NRGOZJYSRXOCFH-UHFFFAOYSA-N 0.000 description 1
- WSSNYTBIOIYFRD-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-[2-(4-chlorophenyl)sulfonylethyl]-4-phenyl-3,4-dihydropyrazole Chemical compound C1=CC(Cl)=CC=C1C(C(C1)C=2C=CC=CC=2)=NN1CCS(=O)(=O)C1=CC=C(Cl)C=C1 WSSNYTBIOIYFRD-UHFFFAOYSA-N 0.000 description 1
- BGXHPWVQZDLJHI-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-[2-(4-chlorophenyl)sulfonylethyl]-4-phenyl-3h-pyrazol-4-ol Chemical compound N1=C(C=2C=CC(Cl)=CC=2)C(O)(C=2C=CC=CC=2)CN1CCS(=O)(=O)C1=CC=C(Cl)C=C1 BGXHPWVQZDLJHI-UHFFFAOYSA-N 0.000 description 1
- OYRYLTWYQHMSAP-UHFFFAOYSA-N 5-(4-chlorophenyl)-4-phenyl-2-[2-[3-(trifluoromethyl)phenyl]sulfonylethyl]-3,4-dihydropyrazole Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)CCN2N=C(C(C2)C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OYRYLTWYQHMSAP-UHFFFAOYSA-N 0.000 description 1
- RBDSMVUZBCAAEN-UHFFFAOYSA-N 5-(4-chlorophenyl)-4-phenyl-n'-(2,4,6-trimethylphenyl)sulfonyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC(=N)N1N=C(C=2C=CC(Cl)=CC=2)C(C=2C=CC=CC=2)C1 RBDSMVUZBCAAEN-UHFFFAOYSA-N 0.000 description 1
- ABGOLZSZPVOQPE-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(3-methoxyphenyl)sulfonyl-n,n-dimethyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound COC1=CC=CC(S(=O)(=O)N=C(N(C)C)N2N=C(C(C2)C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABGOLZSZPVOQPE-UHFFFAOYSA-N 0.000 description 1
- VKGZCXBHRJTWEG-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-4-hydroxy-n,n-dimethyl-4-phenyl-3h-pyrazole-2-carboximidamide Chemical compound C1C(O)(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(N(C)C)=NS(=O)(=O)C1=CC=C(Cl)C=C1 VKGZCXBHRJTWEG-UHFFFAOYSA-N 0.000 description 1
- VHRQDVXOLLGRSP-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-4-phenyl-n-pyridin-2-yl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(\NC=2N=CC=CC=2)=N\S(=O)(=O)C=2C=CC(Cl)=CC=2)CC1C1=CC=CC=C1 VHRQDVXOLLGRSP-UHFFFAOYSA-N 0.000 description 1
- CCXWULHEPDRGMF-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-4-phenyl-n-pyridin-4-yl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(\NC=2C=CN=CC=2)=N\S(=O)(=O)C=2C=CC(Cl)=CC=2)CC1C1=CC=CC=C1 CCXWULHEPDRGMF-UHFFFAOYSA-N 0.000 description 1
- OVBPZWWNLXSVAC-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-n,4-diphenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(\NC=2C=CC=CC=2)=N\S(=O)(=O)C=2C=CC(Cl)=CC=2)CC1C1=CC=CC=C1 OVBPZWWNLXSVAC-UHFFFAOYSA-N 0.000 description 1
- MCYVKBDOPICHID-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-n,n-dimethyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(N(C)C)=NS(=O)(=O)C1=CC=C(Cl)C=C1 MCYVKBDOPICHID-UHFFFAOYSA-N 0.000 description 1
- RKVDQNXSXIWCQP-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-n-(dimethylamino)-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(/NN(C)C)=N\S(=O)(=O)C1=CC=C(Cl)C=C1 RKVDQNXSXIWCQP-UHFFFAOYSA-N 0.000 description 1
- SLWAJDMCAIQFOY-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-n-ethyl-n-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(N(C)CC)=NS(=O)(=O)C1=CC=C(Cl)C=C1 SLWAJDMCAIQFOY-UHFFFAOYSA-N 0.000 description 1
- ATGPYUSOVVWMQP-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-fluorophenyl)sulfonyl-4-hydroxy-4-phenyl-3h-pyrazole-2-carboximidamide Chemical compound C=1C=CC=CC=1C1(O)CN(C(=N)NS(=O)(=O)C=2C=CC(F)=CC=2)N=C1C1=CC=C(Cl)C=C1 ATGPYUSOVVWMQP-UHFFFAOYSA-N 0.000 description 1
- PMFKSNJVULPDBR-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-fluorophenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC(=N)N1N=C(C=2C=CC(Cl)=CC=2)C(C=2C=CC=CC=2)C1 PMFKSNJVULPDBR-UHFFFAOYSA-N 0.000 description 1
- NMOHILMYXVQGHO-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-methyl-4-phenyl-n-[4-(trifluoromethyl)phenyl]sulfonyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(NC)=NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 NMOHILMYXVQGHO-UHFFFAOYSA-N 0.000 description 1
- FAZVAFJOHIBNSU-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-methyl-4-phenyl-n-propan-2-ylsulfonyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound N=1N(C(NS(=O)(=O)C(C)C)=NC)CC(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 FAZVAFJOHIBNSU-UHFFFAOYSA-N 0.000 description 1
- CXFNCCGTEFPLMV-UHFFFAOYSA-N 5-(4-chlorophenyl)-n,n-dimethyl-4-phenyl-n'-[4-(trifluoromethyl)phenyl]sulfonyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(N(C)C)=NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 CXFNCCGTEFPLMV-UHFFFAOYSA-N 0.000 description 1
- GBSRSSIBIGRSBE-UHFFFAOYSA-N 5-(4-chlorophenyl)-n,n-dimethyl-n'-(2-methylphenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(N(C)C)=NS(=O)(=O)C1=CC=CC=C1C GBSRSSIBIGRSBE-UHFFFAOYSA-N 0.000 description 1
- XQWHFCYFPZLONT-UHFFFAOYSA-N 5-(4-chlorophenyl)-n,n-dimethyl-n'-(3-methylphenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(N(C)C)=NS(=O)(=O)C1=CC=CC(C)=C1 XQWHFCYFPZLONT-UHFFFAOYSA-N 0.000 description 1
- WNHXVUIPVMASEZ-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(2,4-difluorophenyl)sulfonyl-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(F)C=C1F WNHXVUIPVMASEZ-UHFFFAOYSA-N 0.000 description 1
- JXUCAZVXNNKWLS-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(3-chlorophenyl)sulfonyl-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=N/C)/NS(=O)(=O)C1=CC=CC(Cl)=C1 JXUCAZVXNNKWLS-UHFFFAOYSA-N 0.000 description 1
- JJRBGSJOVZTHFQ-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-4-phenyl-n'-(2,2,2-trifluoroethyl)-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NCC(F)(F)F)NS(=O)(=O)C1=CC=C(Cl)C=C1 JJRBGSJOVZTHFQ-UHFFFAOYSA-N 0.000 description 1
- AYYMXSJOWFVFIO-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-ethyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NCC)NS(=O)(=O)C1=CC=C(Cl)C=C1 AYYMXSJOWFVFIO-UHFFFAOYSA-N 0.000 description 1
- AXJQVVLKUYCICH-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(Cl)C=C1 AXJQVVLKUYCICH-UHFFFAOYSA-N 0.000 description 1
- NVJVDZMNNYMORJ-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-methyl-4-pyridin-3-yl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=NC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(NC)=NS(=O)(=O)C1=CC=C(Cl)C=C1 NVJVDZMNNYMORJ-UHFFFAOYSA-N 0.000 description 1
- CXNXHKUCYNGGIR-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-methyl-4-pyridin-4-yl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CN=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(Cl)C=C1 CXNXHKUCYNGGIR-UHFFFAOYSA-N 0.000 description 1
- MXVJHHZCQUGIBP-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n-ethyl-4-hydroxy-4-phenyl-3h-pyrazole-2-carboximidamide Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N(CC)C(=N)N(N=1)CC(O)(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 MXVJHHZCQUGIBP-UHFFFAOYSA-N 0.000 description 1
- YZLPWYAHNMXZGM-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-fluorophenyl)sulfonyl-4-phenyl-n'-propan-2-yl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NC(C)C)NS(=O)(=O)C1=CC=C(F)C=C1 YZLPWYAHNMXZGM-UHFFFAOYSA-N 0.000 description 1
- XXYLQSSZLZNJAF-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-fluorophenyl)sulfonyl-4-phenyl-n'-propyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NCCC)NS(=O)(=O)C1=CC=C(F)C=C1 XXYLQSSZLZNJAF-UHFFFAOYSA-N 0.000 description 1
- OCFOYMLWBQDWFN-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-ethyl-n'-(4-fluorophenyl)sulfonyl-n-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(N(C)CC)=NS(=O)(=O)C1=CC=C(F)C=C1 OCFOYMLWBQDWFN-UHFFFAOYSA-N 0.000 description 1
- 241000722948 Apocynum cannabinum Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010056465 Food craving Diseases 0.000 description 1
- 235000015928 Hibiscus cannabinus Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- YNTNKIJUFXILJN-UHFFFAOYSA-N n'-(4-fluorophenyl)sulfonyl-4,5-bis(4-methoxyphenyl)-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(OC)=CC=C1C1C(C=2C=CC(OC)=CC=2)=NN(C(=N)NS(=O)(=O)C=2C=CC(F)=CC=2)C1 YNTNKIJUFXILJN-UHFFFAOYSA-N 0.000 description 1
- LOWNRGJMVVHOEY-UHFFFAOYSA-N n-(4-chlorophenyl)sulfonyl-4-phenyl-n'-propan-2-yl-5-pyridin-4-yl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CN=CC=2)=NN1C(=NC(C)C)NS(=O)(=O)C1=CC=C(Cl)C=C1 LOWNRGJMVVHOEY-UHFFFAOYSA-N 0.000 description 1
- PYXYWJZSZZCOFU-UHFFFAOYSA-N n-(4-chlorophenyl)sulfonyl-5-(5-chlorothiophen-2-yl)-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2SC(Cl)=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(Cl)C=C1 PYXYWJZSZZCOFU-UHFFFAOYSA-N 0.000 description 1
- HLKNXPDTYQPHFF-UHFFFAOYSA-N n-[2-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]ethyl]-3-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)NCCN2N=C(C(C2)C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 HLKNXPDTYQPHFF-UHFFFAOYSA-N 0.000 description 1
- SCJVBJZQVUMHTE-UHFFFAOYSA-N n-[amino-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]methylidene]naphthalene-1-carboxamide Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)N=C(N)N(N=1)CC(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 SCJVBJZQVUMHTE-UHFFFAOYSA-N 0.000 description 1
- QNYKEYVDTHEXKV-UHFFFAOYSA-N n-[amino-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]methylidene]pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(=N)NC(=O)C=2N=CC=CC=2)CC1C1=CC=CC=C1 QNYKEYVDTHEXKV-UHFFFAOYSA-N 0.000 description 1
- IWWDPIHULYTKIS-UHFFFAOYSA-N n-[c-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]-n-methylcarbonimidoyl]-3-(trifluoromethyl)benzamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NC)NC(=O)C1=CC=CC(C(F)(F)F)=C1 IWWDPIHULYTKIS-UHFFFAOYSA-N 0.000 description 1
- SCGPTIIGSPSBRD-UHFFFAOYSA-N n-acetamido-5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(/NNC(=O)C)=N/S(=O)(=O)C1=CC=C(Cl)C=C1 SCGPTIIGSPSBRD-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 208000006155 precocious puberty Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical group CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a group of novel therapeutic and/or prophylactic uses of 4,5-dihydro-1 H-pyrazole derivatives and to pharmaceutical compositions containing one or more of these compounds as an active component for the novel uses.
- the 4,5-dihydro-1 H-pyrazoles are potent Cannabis-1 (CBi) receptor antagonists with outstanding utility for the novel medical uses provided by the present invention.
- Cannabinoids are present in the Indian hemp Cannabis Sativa L. and have been used as medicinal agents for centuries ( echoulam, R.; Feigenbaum, J.J. Prog. Med. Chem. 1987, 24, 159). However, only within the past ten years the research in the cannabinoid area has revealed pivotal information on cannabinoid receptors and their (endogenous) agonists and antagonists. The discovery and the subsequent cloning of two different subtypes of Cannabinoid receptors (CBi and CB 2 ) stimulated the search for novel cannabinoid receptor antagonists (Munro, S.; Thomas, K.L.; Abu-Shaar, M. Nature 1993, 365, 61.
- AM-630 lodopravadoline
- a representative example is lodopravadoline (AM-630), which was introduced in 1995.
- AM-630 is a CBi receptor antagonist, but sometimes behaves as a weak partial agonist (Hosohata, K.; Quock, R.M.; Hosohata, Y.; Burkey, T.H.; Makriyannis, A.; Consroe, P.; Roeske, W.R.; Yamamura, H.I. Life Sc. 1997, 61,
- aryl-aroyl substituted benzofurans as selective CB ! receptor antagonists (e.g. LY -320135) (Felder, CO; Joyce, K.E.; Briley, E.J.; Glass, M.; Mackie, K.P.; Fahey, K.J.; Cullinan, G.J.; Hunden, D.C.; Johnson, D.W.; Chaney, M.O.; Koppel, G.A.; Brownstein, M. J. Pharmacol. Exp. Ther. 1998, 284, 291 ).
- 5-dihydro-1 H-pyrazole compounds which exhibit potent and selective cannabis CB receptor antagonistic activity.
- These compounds have the formula (I) defined below, and have been suggested for use in the treatment of psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as dementia, distonia, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, as well as for the treatment of pain disorders and other CNS-diseases involving cannabinoid neurotransmission, and in the treatment of gastrointestinal disorders and cardiovascular disorders.
- - R and Ri are the same or different and represent phenyl, thienyl or pyridyl which groups may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, from the group C 1-3 -alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C 1-2 )-amino, mono- or dialkyl (C ⁇ -2 )-amido, (d -3 )-alkyl sulfonyl, dimethylsulfamido, C ⁇ -3 -alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, or R and/or R represent naphtyl, - R 2 represents hydrogen, hydroxy, d- 3 -alkoxy
- R 4 and R 5 independently of each other represent hydrogen or C 1 - 8 branched or unbranched alkyl or C 3-8 cycloalkyl or R 4 represents acetamido or dimethylamino or 2,2,2-trifluoroethyl or phenyl or pyridyl with the proviso that R 5 represents hydrogen - R 6 represents hydrogen or C 1-3 unbranched alkyl
- - Bb represents sulfonyl or carbonyl
- R 3 represents benzyl, phenyl, thienyl or pyridyl which may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, or R 3 represents d -8 branched or unbranched alkyl or C 3-8 cycloalkyl, or R 3 represents naphtyl
- the outstanding unique pharmacological profile of compounds of formula (I) includes particularly high safety and tolerability which make the compounds particularly suitable in patient groups with enhanced need of safety and tolerability, in particular such as juvenile patients and/or patients subject to long term treatment, e.g. in drug induced obesity.
- the compounds used according to the invention are suitable for use in the paediatric treatment and/or prophylaxis of psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as dementia, distonia, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, as well as for the treatment of pain disorders and other CNS-diseases involving cannabinoid neurotransmission, and in the treatment of gastrointestinal disorders and cardiovascular disorders, in young patients .
- psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as dementia, distonia, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, as well as for the treatment of pain disorders and other CNS-diseases involving cannabinoid neurotransmission, and in the treatment of gastrointestinal disorders and cardiovascular disorders, in
- the affinity of the compounds of formula (I) for cannabinoid CBi receptors is described in the WO 01/70700, e.g. it was determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabis CBi receptor is stably transfected in conjunction with [3H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand was performed by filtration over glassfiber filters. Radioactivity on the filter was measured by liquid scintillation counting.
- the cannabinoid CBi antagonistic activity of compounds of formula (I) is also described in the WO 01/70700, and was determined by functional studies using CHO cells in which human cannabinoid CB receptors are stably expressed.
- Adenylyl cyclase was stimulated using forskolin and measured by quantifying the amount of accumulated cyclic AMP.
- Concomitant activation of CB ! receptors by CBi receptor agonists e.g. CP -55,940 or (R)-WIN-55,212-2
- CBi receptor agonists e.g. CP -55,940 or (R)-WIN-55,212-2
- This CBi receptor-mediated response can be antagonized by CBi receptor antagonists such as the compounds used in the present invention.
- At least one centre of chirality is present (at the C 4 position of the 4,5-dihydro-1 H- pyrazole moiety) in the compounds of the formula (I).
- the invention relates both to the novel use of racemates, mixtures of diastereomers and the individual stereoisomers of the compounds having formula (I).
- the invention also relates both to the novel use of the E isomer, Z isomer and E/Z mixtures of compounds having formula (I) wherein Aa has the meaning (i) or (ii) as described herein above.
- compound having formula (I) are used, wherein R is the group 4-chlorophenyl, Ri is phenyl, R 2 is hydrogen, Aa is the group (i) wherein R 4 is hydrogen and R 5 is methyl, Bb is sulfonyl, and R 3 represents 4-chlorophenyl, and salts thereof.
- the compound having formula (I) used according to the invention may be a levorotatory enantiomer.
- the compounds used in the present the invention can be obtained according to known methods.
- a suitable synthesis for the compounds used according to the present invention is described for compounds of formula (I) in the international patent application WO 01/70700.
- compounds having formula (III) (vide infra), wherein R 2 represents hydrogen can be also obtained according to methods known, for example: a) EP 0021506; b) DE 2529689.
- Example compounds having been prepared according to WO 01/70700 and being investigated include the e.g. the following compounds:
- N-Dimethylamino-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine N-Methyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine
- the compounds used according to the invention can be brought into forms suitable for paediatric administration, as well as for the administration in treating drug induced obesity by means of usual processes using auxiliary substances and/or liquid or solid carrier materials.
- the invention also pertains to a pharmaceutical composition containing at least one compound of formula (I) as an active component for the treatment and/or prophylaxis of CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients, and at least one auxiliary excipient.
- the compound of formula (I) is preferably present in an amount effectively suited for the treatment and/or prophylaxis of a psychiatric disorder, a gastrointestinal disorder, a cardiovascular disorder, or a combination of said disorders, in a juvenile patient in need of such treating.
- the compound of formula (I) in the pharmaceutical composition is present in an amount effectively suited for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients in need of such treating.
- the invention also includes a method of treatment and/or prophylaxis of
- CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients characterized in that a compound of formula (I) is administered to said patient in need of such treating.
- the method of treatment and/or prophylaxis according to the invention may be further characterized in that the treating is directed to psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, including drug induced obesity, neurological disorders such as Parkinson's disease, dementia, distonia, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, ischemia, pain and other CNS-diseases involving cannabinoid neurotransmission.
- the method of treatment and/or prophylaxis is directed to the treating of obesity in juvenile patients.
- the method of treatment and/or prophylaxis is directed to the treating of drug induced obesity in juvenile or adolescent patients. This drug induced obesity may be in particular caused by drugs like atypical antipsychotics.
- the method of treatment and/or prophylaxis is directed to the treating of obesity in juvenile patients.
- Cannabinoid antagonists are suitable for the treatment of Childhood Obesity and related Comorbidities as for example Type 2 Diabetes.
- Childhood Obesity and related Comorbidities as for example Type 2 Diabetes.
- the prevalence of overweight in children grew from 5% to 11 % (Sorof and Daniels 2002).
- Obesity in childhood causes a wide range of serious complications, and increases the risk of premature illness and death later in life, raising public-health concerns (Ebbeling,
- Type-2-diabetes was in the past considered a disease of adults and older individuals, not a paediatric condition (Arslanian 2002).
- One of the main risk factor of paediatric type 2 diabetes is obesity.
- Type 2 diabetes in children is part of the insulin resistance syndrome (Rosenbloom 2002) that includes hypertension, dyslipidemia and other atherosclerosis risk factors, and hyperandrogenism seen as premature adrenarche and polycystic ovary syndrome.
- Other outcomes related to childhood obesity include left ventricular hypertrophy, nonalcoholic steatohepatitis, obstructive sleep apnea, orthopedic problems, and severe psychosocial problems.
- CBi antagonists used according to the present invention offer a unique opportunity for the treatment of obesity by interacting with these "driving forces".
- CBi antagonists in childhood are a medical condition that is likely to require long-term management.
- the safety profile of CBi antagonists according to the present invention are suggested to be superior to current standard medications, and these CBi antagonists will be especially suited for the treatment and prevention of childhood obesity and related co-morbidities.
- the method of treatment and/or prophylaxis is directed to the treating of drug induced obesity in juvenile or adolescent patients.
- Drug induced weight gain is also of major concern and subject to high medical need of improved treatments.
- the CBi antagonists according to the present invention are suggested to be superior to current standard medications, and these CB ! antagonists will be especially suited for the treatment and prevention of drug induced obesity in juvenile as well as in adolescent patients.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to a novel medical use of 4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the cannabis CB1-receptor. Said compounds are particularly suitable in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The compounds have the general formula (1), wherein the group Bb represents sulfonyl or carbonyl, and the substituents R, R1, R2and R3, and the group Aa are defined as shown in the description.
Description
4 , 5-DIHYDRO- lH-PYRAZOLE DERIVATIVES HAVING CBl-ANTAGONISTIC ACTIVITY
The present invention relates to a group of novel therapeutic and/or prophylactic uses of 4,5-dihydro-1 H-pyrazole derivatives and to pharmaceutical compositions containing one or more of these compounds as an active component for the novel uses. The 4,5-dihydro-1 H-pyrazoles are potent Cannabis-1 (CBi) receptor antagonists with outstanding utility for the novel medical uses provided by the present invention.
Cannabinoids are present in the Indian hemp Cannabis Sativa L. and have been used as medicinal agents for centuries ( echoulam, R.; Feigenbaum, J.J. Prog. Med. Chem. 1987, 24, 159). However, only within the past ten years the research in the cannabinoid area has revealed pivotal information on cannabinoid receptors and their (endogenous) agonists and antagonists. The discovery and the subsequent cloning of two different subtypes of Cannabinoid receptors (CBi and CB2) stimulated the search for novel cannabinoid receptor antagonists (Munro, S.; Thomas, K.L.; Abu-Shaar, M. Nature 1993, 365, 61. Matsuda, L.A.; Bonner, T.I. Cannabinoid Receptors, Pertwee, R.G. Ed. 1995, 1 17, Academic Press, London). In addition, pharmaceutical companies became interested in the development of cannabinoid drugs for the treatment of diseases connected with disorders of the cannabinoid system. The wide distribution of CBT receptors in the brain, in combination with the strictly peripheral localisation of the CB2 receptor, makes the CB! receptor a very interesting molecular target for CNS-directed drug discovery in the areas of both psychiatric and neurological disorders (Consroe, P. Neurobiology of Disease 1998, 5, 534. Pop, E. Curr. Opin. In CPNS
Investigational Drugs 1999, 1, 587. Greenberg, D.A. Drug News Perspect. 1999, 12, 458). Hitherto, three types of distinct CBi receptor antagonists are known. Sanofi disclosed their diarylpyrazole congeners as selective CBi receptor antagonists. A representative example is SR-141716A, which is currently undergoing Phase II clinical development for psychotic disorders (Dutta, A.K.;
Sard, H.; Ryan, W.; Razdan, R.K.; Compton, D.R.; Martin, B.R. Med. Chem. Res. 1994, 5, 54. Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S.R.; McCallion, D.; Pertwee, R.; Makriyannis, A. J. Med. Chem. 1999, 42, 769. Nakamura-Palacios, E.M.; Moerschbaecher, J.M.; Barker, L.A. CNS Drug Rev. 1999, 5, 43).
Aminoalkylindoles have been disclosed as CB T receptor antagonists. A representative example is lodopravadoline (AM-630), which was introduced in 1995. AM-630 is a CBi receptor antagonist, but sometimes behaves as a weak partial agonist (Hosohata, K.; Quock, R.M.; Hosohata, Y.; Burkey, T.H.; Makriyannis, A.; Consroe, P.; Roeske, W.R.; Yamamura, H.I. Life Sc. 1997, 61,
PL115). More recently, researchers from Eli Lilly described aryl-aroyl substituted benzofurans as selective CB! receptor antagonists (e.g. LY -320135) (Felder, CO; Joyce, K.E.; Briley, E.J.; Glass, M.; Mackie, K.P.; Fahey, K.J.; Cullinan, G.J.; Hunden, D.C.; Johnson, D.W.; Chaney, M.O.; Koppel, G.A.; Brownstein, M. J. Pharmacol. Exp. Ther. 1998, 284, 291 ). Recently, 3-alkyl-5,5'- diphenylimidazolidinediones were described as cannabinoid receptor ligands, which were indicated to be cannabinoid antagonists (Kanyonyo, M.; Govaerts, S.J.; Hermans, E.; Poupaert, J.H., Lambert, D.M. Biorg. Med.Chem. Lett. 1999, 9, 2233). Interestingly, many CBi receptor antagonists have been reported to behave as inverse agonists in vitro (Landsman, R.S.; Burkey, T.H.; Consroe, P.;
Roeske, W.R.; Yamamura, H.I. Eur. J. Pharmacol. 1997 , 334, R1). Recent reviews provide a nice overview of the current status in the cannabinoid research area (Mechoulam, R.; Hanus, L.; Fride, E. Prog. Med. Chem. 1998, 35, 199. Lambert, D.M. Curr. Med. Chem. 1999, 6, 635. Mechoulam, R.; Fride, E.; Di Marzo, V. Eur. J. Pharmacol. 1998, 359, 1 ).
From the international patent application WO 01/70700 4, 5-dihydro-1 H-pyrazole compounds are known which exhibit potent and selective cannabis CB receptor antagonistic activity. These compounds have the formula (I) defined below, and have been suggested for use in the treatment of psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as dementia, distonia, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, as well as for the treatment of pain disorders and other CNS-diseases involving cannabinoid neurotransmission, and in the treatment of gastrointestinal disorders and cardiovascular disorders.
It has now surprisingly been found that the 4,5-dihydro-1 H-pyrazole derivatives of the formula (I) which are potent and selective antagonists of the cannabis CBi- receptor, prodrugs thereof, tautomers thereof and salts thereof
wherein - R and Ri are the same or different and represent phenyl, thienyl or pyridyl which groups may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, from the group C1-3-alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C1-2)-amino, mono- or dialkyl (Cι-2)-amido, (d-3)-alkyl sulfonyl, dimethylsulfamido, Cι-3-alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, or R and/or R represent naphtyl, - R2 represents hydrogen, hydroxy, d-3-alkoxy, acetyloxy or propionyloxy, - Aa represents one of the groups (i), (ii), (iii), (iv) or (v)
(i) (ϋ) (iϋ) (iv) (v) wherein - R4 and R5 independently of each other represent hydrogen or C1-8 branched or unbranched alkyl or C3-8 cycloalkyl or R4 represents acetamido or dimethylamino or 2,2,2-trifluoroethyl or phenyl or pyridyl with the proviso that R5 represents hydrogen - R6 represents hydrogen or C1-3 unbranched alkyl
- Bb represents sulfonyl or carbonyl, - R3 represents benzyl, phenyl, thienyl or pyridyl which may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, or R3 represents d-8 branched or unbranched alkyl or C3-8 cycloalkyl, or R3 represents naphtyl
due to their unique pharmacological profile are particularly suited for the use in
the manufacture of a medicaments for the treatment and/or prophylaxis of CB-1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis drug induced obesity in juvenile, as well as adolescent, patients. In this regard the compounds of formula (I) are highly valuable in providing medicaments for paediatric use on the one hand, and for the general use in drug induced obesity.
The outstanding unique pharmacological profile of compounds of formula (I) includes particularly high safety and tolerability which make the compounds particularly suitable in patient groups with enhanced need of safety and tolerability, in particular such as juvenile patients and/or patients subject to long term treatment, e.g. in drug induced obesity.
Due to the potent CBT antagonistic activity the compounds used according to the invention are suitable for use in the paediatric treatment and/or prophylaxis of psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as dementia, distonia, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, as well as for the treatment of pain disorders and other CNS-diseases involving cannabinoid neurotransmission, and in the treatment of gastrointestinal disorders and cardiovascular disorders, in young patients .
The affinity of the compounds of formula (I) for cannabinoid CBi receptors is described in the WO 01/70700, e.g. it was determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabis CBi receptor is stably transfected in conjunction with [3H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand was performed by filtration over glassfiber filters. Radioactivity on the filter was measured by liquid scintillation counting.
The cannabinoid CBi antagonistic activity of compounds of formula (I) is also described in the WO 01/70700, and was determined by functional studies using CHO cells in which human cannabinoid CB receptors are stably expressed.
Adenylyl cyclase was stimulated using forskolin and measured by quantifying the amount of accumulated cyclic AMP. Concomitant activation of CB! receptors by CBi receptor agonists (e.g. CP -55,940 or (R)-WIN-55,212-2) can attenuate the forskolin-induced accumulation of cAMP in a concentration -dependent manner.
This CBi receptor-mediated response can be antagonized by CBi receptor antagonists such as the compounds used in the present invention.
The whole content of the international patent application WO 01/70700 is incorporated by reference into the present application.
At least one centre of chirality is present (at the C4 position of the 4,5-dihydro-1 H- pyrazole moiety) in the compounds of the formula (I). The invention relates both to the novel use of racemates, mixtures of diastereomers and the individual stereoisomers of the compounds having formula (I). The invention also relates both to the novel use of the E isomer, Z isomer and E/Z mixtures of compounds having formula (I) wherein Aa has the meaning (i) or (ii) as described herein above.
According to one embodiment of the invention compound having formula (I) are used, wherein R is the group 4-chlorophenyl, Ri is phenyl, R2 is hydrogen, Aa is the group (i) wherein R4 is hydrogen and R5 is methyl, Bb is sulfonyl, and R3 represents 4-chlorophenyl, and salts thereof. The compound having formula (I) used according to the invention may be a levorotatory enantiomer.
The compounds used in the present the invention can be obtained according to known methods. A suitable synthesis for the compounds used according to the present invention is described for compounds of formula (I) in the international patent application WO 01/70700. For example compounds having formula (III) (vide infra), wherein R2 represents hydrogen can be also obtained according to methods known, for example: a) EP 0021506; b) DE 2529689.
Example compounds having been prepared according to WO 01/70700 and being investigated include the e.g. the following compounds:
1 ) 3-(4-Chlorophenyl)-4,5-dihydro-4-hydroxy-4-phenyl-1 H-pyrazole 2) 3-(4-Chlorophenyl)-4,5-dihydro-N-((4-fluorophenyl)sulfonyl)-4-phenyl-1 H- pyrazole-1 -carboxamidine 3) 4,5-Dihydro-N-((4-fluorophenyl)sulfonyl)-3-(4-methoxyphenyl)-4-(4- methoxy-phenyl)-1 H-pyrazole-1 -carboxamidine 4) 4,5-Dihydro-3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-N-((4-methoxy- phenyl)sulfonyl)-1 H-pyrazole-1 -carboxamidine 5) 3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-N-((2,4,6- trimethylphenyl)sulfonyl)-1 H-pyrazole-1 -carboxamidine
6) 3-(4-Chlorophenyl)-4,5-dihydro-N-((4-fluorophenyl)sulfonyl)-4-hydroxy-4- phenyl-1 H-pyrazole-1 -carboxamidine
7) 3-(4-Chlorophenyl)-4,5-dihydro-N-(1 -naphtoyl)-4-phenyl-1 H-pyrazole-1 - carboxamidine 8) 3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-N-(2-pyridoyl)-1 H-pyrazole-1 - carboxamidine 9) N ,N1-Dimethyl-N2-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine 10) N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- (3-pyridyl)-1 H-pyrazole-1 -carboxamidine
11 ) N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- (4-pyridyl)-1 H-pyrazole-1 -carboxamidine 12) N1,N1-Dimethyl-N2-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-hydroxy-4-phenyl-1 H-pyrazole-1 -carboxamidine 13) N-Ethyl-N-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- hydroxy-4-phenyl-1 H-pyrazole-1 -carboxamidine
14) N-Methyl-N'-(3-(trifluoromethyl)benzoyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine 15) N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine 16) N-Methyl-N'-((3-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl -1 H-pyrazole-1 -carboxamidine 17) N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(5-chloro-2-thienyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine
18) N-Propyl-N'-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine 19) N-(2-Propyl)-N'-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro- 4-phenyl-1 H-pyrazole-1 -carboxamidine 20) N-Methyl-N'-((2-propyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl- 1 H-pyrazole-1 -carboxamidine 21 ) N-(2-Propyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-pyridyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine 22) N1-Ethyl-N1-methyl-N2-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine
23) N1-Ethyl-N1-methyl-N2-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine 24) N1,N1-Dimethyl-N2-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(4-chlorophenyl)- 4,5-dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine
N1,N1-Dimethyl-N2-((3-methylphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine N1,N1-Dimethyl-N2-((3-methoxyphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine N-Ethyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine
N-Dimethylamino-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine N-Methyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine N1,N1-Dimethyl-N2-((2-methylphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine
N-Methyl-N'-((2,4-difluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro- 4-phenyl-1 H-pyrazole-1 -carboxamidine
N-Acetamido-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro- 4-phenyl-1 H-pyrazole-1 -carboxamidine
N-(2,2,2-Trifluoroethyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)- 4,5-dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine N-(2-Pyridyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro- 4-phenyl -1 H-pyrazole-1 -carboxamidine
N-(4-Pyridyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro- 4-phenyl -1 H-pyrazole-1 -carboxamidine
N-Phenyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl -1 H-pyrazole-1 -carboxamidine
3-(4-Chlorophenyl)-1-[3-((4-chlorophenyl)sulfonyl)butanoyl]-4,5-dihydro-4- phenyl-1 H-pyrazole
3-(4-Chlorophenyl)-1-[3-(phenylsulfonyl)propanoyl]-4,5-dihydro-4-phenyl- 1 H-pyrazole
3-(4-Chlorophenyl)-1-[3-((4-chlorophenyl)sulfonyl)propanoyl]-4,5-dihydro- 4-phenyl-1 H-pyrazole
3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-1-[2-((3-(trifluoromethyl)phenyl)- sulfonyl)ethyl]-1 H-pyrazole
3-(4-Chlorophenyl)-1-[2-(benzylsulfonyl)ethyl]-4,5-dihydro-4-phenyl-1 H- pyrazole
3-(4-Chlorophenyl)-1-[2-((4-chlorophenyl)sulfonyl)ethyl]-4,5-dihydro-4- phenyl-1 H-pyrazole
3-(4-Chlorophenyl)-1-[2-((4-chlorophenyl)sulfonyl)ethyl]-4,5-dihydro-4- hydroxy-4-phenyl-1 H-pyrazole
44) N-[2-(3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-1 H-pyrazol-1 -yl)ethyl]-3- (trifluoromethyl)benzenesulfonamide
The compounds used according to the invention can be brought into forms suitable for paediatric administration, as well as for the administration in treating drug induced obesity by means of usual processes using auxiliary substances and/or liquid or solid carrier materials.
Hence, in a further aspect the invention also pertains to a pharmaceutical composition containing at least one compound of formula (I) as an active component for the treatment and/or prophylaxis of CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients, and at least one auxiliary excipient. In such a pharmaceutical composition the compound of formula (I) is preferably present in an amount effectively suited for the treatment and/or prophylaxis of a psychiatric disorder, a gastrointestinal disorder, a cardiovascular disorder, or a combination of said disorders, in a juvenile patient in need of such treating.
In a further embodiment of the invention in the pharmaceutical composition the compound of formula (I) is present in an amount effectively suited for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients in need of such treating.
Finally the invention also includes a method of treatment and/or prophylaxis of
CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients, characterized in that a compound of formula (I) is administered to said patient in need of such treating. The method of treatment and/or prophylaxis according to the invention may be further characterized in that the treating is directed to psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, including drug induced obesity, neurological disorders such as Parkinson's disease, dementia, distonia, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, ischemia, pain and other CNS-diseases involving cannabinoid neurotransmission.
Preferably, in one embodiment of the invention the method of treatment and/or prophylaxis is directed to the treating of obesity in juvenile patients. In another preferred embodiment of the invention the method of treatment and/or prophylaxis is directed to the treating of drug induced obesity in juvenile or
adolescent patients. This drug induced obesity may be in particular caused by drugs like atypical antipsychotics.
In one embodiment of the invention the method of treatment and/or prophylaxis is directed to the treating of obesity in juvenile patients. Thus, it is advantageous that Cannabinoid antagonists are suitable for the treatment of Childhood Obesity and related Comorbidities as for example Type 2 Diabetes. There is a clear medical need for improved therapy as obesity has become an increasingly important medical problem not only in the adult population but increasingly in children and (young and older) adolescents. In national surveys from the 1960s to the 1990s in the United States, the prevalence of overweight in children grew from 5% to 11 % (Sorof and Daniels 2002). In Canada as another example childhood obesity has tripled in the past 20 years (Spurgeon 2002). Obesity in childhood causes a wide range of serious complications, and increases the risk of premature illness and death later in life, raising public-health concerns (Ebbeling,
Pawlak et al. 2002). Over the last decades a tremendous increase of cases of type 2 diabetes was observed, especially also in children. This epidemic trend is clearly reflecting the increasing rates of obesity. Type-2-diabetes was in the past considered a disease of adults and older individuals, not a paediatric condition (Arslanian 2002). One of the main risk factor of paediatric type 2 diabetes is obesity.
Type 2 diabetes in children (as is in adults) is part of the insulin resistance syndrome (Rosenbloom 2002) that includes hypertension, dyslipidemia and other atherosclerosis risk factors, and hyperandrogenism seen as premature adrenarche and polycystic ovary syndrome. Other outcomes related to childhood obesity include left ventricular hypertrophy, nonalcoholic steatohepatitis, obstructive sleep apnea, orthopedic problems, and severe psychosocial problems.
In addition primary hypertension has become increasingly common in children again associated obesity as a major independent risk factor. Obese children are at approximately a 3-fold higher risk for hypertension than non-obese children (Sorof and Daniels 2002). The benefits of weight loss for blood pressure reduction in children have been demonstrated in both observational and interventional studies.
Public concerns are rising because of a rapid development of the childhood obesity epidemic in genetically stable populations. Driving factors are assumed to
be mainly adverse environmental factors for which straightforward recommendations of life style modifications exists. Obesity and it's related co- morbidities are very serious medical conditions and state of the art measures and treatment of obesity and especially childhood obesity remain largely ineffective at the time being (Ebbeling, Pawlak et al. 2002). The management of type 2 diabetes in is also especially difficult in children and the adolescent age group (Silink 2002). Craving for and over consumption of palatable food is one of the important factors of life-style related obesity in humans and especially also in children and adolescents. Treatment of type 2 diabetes and other co-morbid conditions by the degree of metabolic derangement and symptoms: The only data on the use of oral hypoglycemic agents in children with type 2 diabetes has been with metformin (Rosenbloom 2002).
Thus, CBi antagonists used according to the present invention offer a unique opportunity for the treatment of obesity by interacting with these "driving forces".
They are superior to current medical treatments and especially suited for pediatric treatment because of their outstanding safety profile and/or tolerability. Treatment of obesity especially childhood obesity is besides efficacy dictated by safety.
Obesity in childhood is a medical condition that is likely to require long-term management. The safety profile of CBi antagonists according to the present invention are suggested to be superior to current standard medications, and these CBi antagonists will be especially suited for the treatment and prevention of childhood obesity and related co-morbidities.
Literature:
Arslanian, S. (2002). "Type 2 diabetes in children: clinical aspects and risk factors." Horm Res 57 Suppl 1 : 19-28. Ebbeling, C. B., D. B. Pawlak, et al. (2002). "Childhood obesity: public-health crisis, common sense cure." Lancet 360(9331 ): 473-82.
Rosenbloom, A. L. (2002). "Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations." Paediatr Drugs 4(4): 209-21.
Silink, M. (2002). "Childhood diabetes: a global perspective." Horm Res 57 Suppl 1 : 1-5.
Sorof, J. and S. Daniels (2002). "Obesity hypertension in children: a problem of epidemic proportions." Hypertension 40(4): 441 -7.
Spurgeon, D. (2002). "Childhood obesity in Canada has tripled in past 20 years." Bmi 324(7351 ): 1416.
In another embodiment of the invention the method of treatment and/or prophylaxis is directed to the treating of drug induced obesity in juvenile or adolescent patients. Drug induced weight gain is also of major concern and subject to high medical need of improved treatments. Again, in this context the CBi antagonists according to the present invention are suggested to be superior to current standard medications, and these CB! antagonists will be especially suited for the treatment and prevention of drug induced obesity in juvenile as well as in adolescent patients.
Regarding drug induced weight gain, it is reported by Zimmermann, U., T. Kraus, et al. (2003, "Epidemiology, implications and mechanisms underlying drug- induced weight gain in psychiatric patients." J Psychiatr Res 37(3): 193-220) that body weight gain frequently occurs during drug treatment of psychiatric disorders and is often accompanied by increased appetite or food craving. While occurrence and time course of this side effect are difficult to predict, it ultimately results in obesity and the morbidity associated therewith in a substantial part of patients, often causing them to discontinue treatment even if it is effective. Weight gain appears to be most prominent in patients treated with some of the second generation antipsychotic drugs and with some mood stabilizers. Marked weight gain also frequently occurs during treatment with most tricyclic antidepressants.
Very large weight gains are associated with drugs like for example the atypical antipsychotics clozapine and olanzapine. Some atypical antipsychotics, however, tend to cause significant weight gain, which may lead to poor compliance and other adverse health effects (Nasrallah, H. (2003). "A review of the effect of atypical antipsychotics on weight." Psychoneuroendocrinology 28 Suppl 1 : 83- 96.). The mechanisms involved in antipsychotic drug-related weight gain are as yet uncertain, although serotoninergic, histaminic, and adrenergic affinities have been implicated along with other metabolic mechanisms. The atypical antipsychotics vary in their propensity to cause weight change with long-term treatment. Follow-up studies show that the largest weight gains are associated with clozapine and olanzapine, and the smallest with quetiapine and ziprasidone. Risperidone is associated with modest weight changes that are not dose related.
Given the equivalent efficacy of atypical antipsychotics, weight-gain profile is a legitimate factor to consider when constructing an algorithm for treatment due to the serious medical consequences of obesity. In this regard co-administration of CBT antagonist according to the invention is suggested to work beneficially.
Claims
1. Use of a CB1 receptor antagonistic compound of formula (I), prodrugs thereof, tautomers thereof and salts thereof, in the manufacture of medicaments for the treatment and/or prophylaxis of CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients:
wherein - R and Ri are the same or different and represent phenyl, thienyl or pyridyl which groups may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, from the group Cι-3-alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C1-2)-amino, mono- or dialkyl (C1-2)-amido, (C1-3)-alkyl sulfonyl, dimethylsulfamido, Cι-3-alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, or R and/or RT represent naphtyl, - R2 represents hydrogen, hydroxy, C1-3-alkoxy, acetyloxy or propionyloxy, - Aa represents one of the groups (i), (ii), (iii), (iv) or (v)
(i) (ϋ) (iii) (iv) (v) wherein R4 a nd R independently of each other represent hydrogen or C1-8 branched or unbranched alkyl or C3-8 cycloalkyl or R4 represents acetamido or dimethylamino or 2,2,2-trifluoroethyl or phenyl or pyridyl with the proviso that R5 represents hydrogen - R6 represents hydrogen or Cι-3 unbranched alkyl - Bb represents sulfonyl or carbonyl, - R3 represents benzyl, phenyl, thienyl or pyridyl which may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, or R3 represents C1.8 branched or unbranched alkyl or C3-8 cycloalkyl, or R3 represents naphtyl.
2. Use of the compound having formula (I) according to claim 1 , wherein R is the group 4-chlorophenyl, Ri is phenyl, R2 is hydrogen, Aa is the group (i) wherein R4 is hydrogen and R5 is methyl, Bb is sulfonyl, and R3 represents 4- chlorophenyl, and salts thereof.
3. Use of the compound having formula (I) according to claim 1 , wherein the compound is a levorotatory enantiomer.
4. A pharmaceutical composition containing at least one compound of formula (I) as defined in claim 1 as an active component for the treatment and/or prophylaxis of CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients, and at least one auxiliary excipient.
5. A pharmaceutical composition according to claim 4, wherein the at least one compound of formula (I) is present in an amount effectively suited for the treatment and/or prophylaxis of a psychiatric disorder, a gastrointestinal disorder, a cardiovascular disorder, or a combination of said disorders, in a juvenile patient in need of such treating.
6. A pharmaceutical composition according to claim 4, wherein the at least one compound of formula (I) is present in an amount effectively suited for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients in need of such treating.
7. A method of treatment and/or prophylaxis of CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients, characterized in that a compound of formula (I) as defined in claim 1 is administered to said patient in need of such treating.
8. A method of treatment and/or prophylaxis according to claim 7, characterized in that the treating is directed to psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, including drug induced obesity, neurological disorders such as Parkinson's disease, dementia, distonia, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, ischaemia, pain and other CNS-diseases involving cannabinoid neurotransmission.
9. A method of treatment and/or prophylaxis according to claim 8, characterized in that the treating is directed to obesity in juvenile patients.
10. A method of treatment and/or prophylaxis according to claim 8, characterized in that the treating is directed to drug induced obesity in juvenile or adolescent patients.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXPA06002365A MXPA06002365A (en) | 2003-09-02 | 2004-08-31 | Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity. |
| AU2004268388A AU2004268388A1 (en) | 2003-09-02 | 2004-08-31 | Use of 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
| CA002537090A CA2537090A1 (en) | 2003-09-02 | 2004-08-31 | Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| BRPI0413980-1A BRPI0413980A (en) | 2003-09-02 | 2004-08-31 | use of 4,5-dihydro-1h-pyrazole derivatives with cb1 antagonist activity |
| EP04766644A EP1663205A1 (en) | 2003-09-02 | 2004-08-31 | Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| JP2006525143A JP2007504200A (en) | 2003-09-02 | 2004-08-31 | Use of 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03019939 | 2003-09-02 | ||
| EP03019939.2 | 2003-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005020988A1 true WO2005020988A1 (en) | 2005-03-10 |
Family
ID=34259159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2004/051961 WO2005020988A1 (en) | 2003-09-02 | 2004-08-31 | Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1663205A1 (en) |
| JP (1) | JP2007504200A (en) |
| CN (2) | CN1835747A (en) |
| AR (1) | AR045533A1 (en) |
| AU (1) | AU2004268388A1 (en) |
| BR (1) | BRPI0413980A (en) |
| CA (1) | CA2537090A1 (en) |
| MX (1) | MXPA06002365A (en) |
| RU (1) | RU2006110543A (en) |
| TW (1) | TW200511990A (en) |
| WO (1) | WO2005020988A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7348456B2 (en) | 2002-12-19 | 2008-03-25 | Merck & Co., Inc. | Substituted amides |
| US7700597B2 (en) | 2004-12-03 | 2010-04-20 | Schering Corporation | Substituted piperazines as CB1 antagonists |
| WO2009140210A3 (en) * | 2008-05-12 | 2010-08-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Radiotracers for imaging cannabinoid sub-type1 (cb1) receptor |
| US9238027B2 (en) | 2009-01-12 | 2016-01-19 | Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (Fuhnpaiin) | Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070700A1 (en) * | 2000-03-23 | 2001-09-27 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| WO2002076949A1 (en) * | 2001-03-22 | 2002-10-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| WO2003026647A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
-
2004
- 2004-08-30 AR ARP040103109A patent/AR045533A1/en not_active Application Discontinuation
- 2004-08-30 TW TW093125980A patent/TW200511990A/en unknown
- 2004-08-31 CN CNA2004800234935A patent/CN1835747A/en active Pending
- 2004-08-31 MX MXPA06002365A patent/MXPA06002365A/en not_active Application Discontinuation
- 2004-08-31 EP EP04766644A patent/EP1663205A1/en not_active Withdrawn
- 2004-08-31 JP JP2006525143A patent/JP2007504200A/en active Pending
- 2004-08-31 RU RU2006110543/15A patent/RU2006110543A/en not_active Application Discontinuation
- 2004-08-31 WO PCT/EP2004/051961 patent/WO2005020988A1/en active Application Filing
- 2004-08-31 CA CA002537090A patent/CA2537090A1/en not_active Abandoned
- 2004-08-31 CN CNA2004800248995A patent/CN1845735A/en active Pending
- 2004-08-31 AU AU2004268388A patent/AU2004268388A1/en not_active Abandoned
- 2004-08-31 BR BRPI0413980-1A patent/BRPI0413980A/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070700A1 (en) * | 2000-03-23 | 2001-09-27 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| WO2002076949A1 (en) * | 2001-03-22 | 2002-10-03 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| WO2003026647A1 (en) * | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
Non-Patent Citations (1)
| Title |
|---|
| HERREMANS A H J ET AL: "SLV319, A MOLECULE WITH CANNABINOID CB1 RECEPTOR ANTAGONIST PROPERTIES in vitro AND in vivo.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, 32nd Annual Meeting of the Society for Neuroscience;Orlando, Florida, USA; November 02-07, 2002, pages Abstract No. 783.17, XP009023988 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7348456B2 (en) | 2002-12-19 | 2008-03-25 | Merck & Co., Inc. | Substituted amides |
| US7576239B2 (en) | 2002-12-19 | 2009-08-18 | Merck & Co., Inc. | Substituted amides |
| US7700597B2 (en) | 2004-12-03 | 2010-04-20 | Schering Corporation | Substituted piperazines as CB1 antagonists |
| WO2009140210A3 (en) * | 2008-05-12 | 2010-08-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Radiotracers for imaging cannabinoid sub-type1 (cb1) receptor |
| US9238027B2 (en) | 2009-01-12 | 2016-01-19 | Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (Fuhnpaiin) | Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability |
| US9592237B2 (en) | 2009-01-12 | 2017-03-14 | Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (Fuhnpaiin) | Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004268388A1 (en) | 2005-03-10 |
| MXPA06002365A (en) | 2006-06-20 |
| BRPI0413980A (en) | 2006-11-07 |
| TW200511990A (en) | 2005-04-01 |
| RU2006110543A (en) | 2007-10-10 |
| CA2537090A1 (en) | 2005-03-10 |
| CN1835747A (en) | 2006-09-20 |
| JP2007504200A (en) | 2007-03-01 |
| CN1845735A (en) | 2006-10-11 |
| AR045533A1 (en) | 2005-11-02 |
| EP1663205A1 (en) | 2006-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lange et al. | Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists | |
| CN101861151B (en) | Cancer combination therapy with a selective inhibitor of histone deacetylase HDAC1, HDAC2 and/or HDAC3 and a microtubule stabilizer | |
| AU2003254650B2 (en) | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | |
| US20050101585A1 (en) | Use of selective CB1-antagonists in medical treatments | |
| ZA200402099B (en) | Novel 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity. | |
| US20050124660A1 (en) | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds | |
| HRP980042A2 (en) | Use of central cannabinoid receptor antagonists for the preparation of drugs | |
| US20050080125A1 (en) | Novel medical uses of 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
| TW200812576A (en) | Novel use of CBx cannabinoid receptor modulators as potassium channel modulators | |
| WO2005020988A1 (en) | Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
| JP2009534439A (en) | Pharmaceutical composition comprising CBX cannabinoid receptor modulator and potassium channel modulator | |
| WO2005039550A2 (en) | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds | |
| HK1093316A (en) | Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
| EP1680106B1 (en) | Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors | |
| US20050143441A1 (en) | Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
| HK1092062A (en) | Novel medical use of selective cb1-receptor antagonists | |
| JP2006096664A (en) | Liver fibrosis inhibitor | |
| KR20050057272A (en) | Preventive and/or therapeutic drugs for inflammatory intestinal diseases | |
| HK1128229A (en) | Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators | |
| JP2008037753A (en) | Treatment and / or prevention agent for pruritus | |
| CA2518579A1 (en) | Method for appetite suppression | |
| WO2007009692A1 (en) | Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes | |
| HK1149213A (en) | Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer | |
| JP2006298786A (en) | 2-methyl-1,3,4-thiadiazole-5-thiol production inhibitor | |
| HK1102368A (en) | Use of an antagonist of cb1 receivers associated with a beta3-agonist for preparing medication to be used for treating appetence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200480023493.5 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2004766644 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2537090 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/002365 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004268388 Country of ref document: AU Ref document number: 2006525143 Country of ref document: JP |
|
| ENP | Entry into the national phase |
Ref document number: 2004268388 Country of ref document: AU Date of ref document: 20040831 Kind code of ref document: A |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004268388 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006110543 Country of ref document: RU |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004766644 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: PI0413980 Country of ref document: BR |